206 related articles for article (PubMed ID: 30529931)
1. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump.
Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS
J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931
[TBL] [Abstract][Full Text] [Related]
2. Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c.
Cloete R; Kapp E; Joubert J; Christoffels A; Malan SF
PLoS One; 2018; 13(11):e0207605. PubMed ID: 30475855
[TBL] [Abstract][Full Text] [Related]
3. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
4. In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis.
Biswas SS; Browne RB; Borah VV; Roy JD
Appl Biochem Biotechnol; 2021 Jun; 193(6):1757-1779. PubMed ID: 33826064
[TBL] [Abstract][Full Text] [Related]
5. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.
Gupta AK; Katoch VM; Chauhan DS; Sharma R; Singh M; Venkatesan K; Sharma VD
Microb Drug Resist; 2010 Mar; 16(1):21-8. PubMed ID: 20001742
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K
ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555
[TBL] [Abstract][Full Text] [Related]
7. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
Ramón-García S; Martín C; Thompson CJ; Aínsa JA
Antimicrob Agents Chemother; 2009 Sep; 53(9):3675-82. PubMed ID: 19564371
[TBL] [Abstract][Full Text] [Related]
8. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.
Rodrigues L; Machado D; Couto I; Amaral L; Viveiros M
Infect Genet Evol; 2012 Jun; 12(4):695-700. PubMed ID: 21871582
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
10. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol.
Gupta AK; Reddy VP; Lavania M; Chauhan DS; Venkatesan K; Sharma VD; Tyagi AK; Katoch VM
Indian J Med Res; 2010 Aug; 132():176-88. PubMed ID: 20716818
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding studies of
Mallavarapu BD; Abdullah M; Saxena S; Guruprasad L
J Biomol Struct Dyn; 2019 Sep; 37(14):3751-3763. PubMed ID: 30239262
[TBL] [Abstract][Full Text] [Related]
12. Reduction of minimum inhibitory concentrations in drug-resistant Mycobacterium tuberculosis isolates in the presence of efflux pump inhibitors.
Yadav R; Dhatwalia SK; Mewara A; Behera D; Sethi S
J Glob Antimicrob Resist; 2016 Jun; 5():88-9. PubMed ID: 27436475
[No Abstract] [Full Text] [Related]
13. Modification of drug-binding proteins associated with the efflux pump in MDR-MTB in course of evolution: an unraveled clue based on in silico approach.
Panja AS; Sarkar A; Biswas R; Bandyopadhyay B; Bandopadhyay R
J Antibiot (Tokyo); 2019 May; 72(5):282-290. PubMed ID: 30799437
[TBL] [Abstract][Full Text] [Related]
14. Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis.
Caleffi-Ferracioli KR; Cardoso RF; de Souza JV; Murase LS; Canezin PH; Scodro RB; Ld Siqueira V; Pavan FR
Future Microbiol; 2019 Feb; 14():185-194. PubMed ID: 30648892
[TBL] [Abstract][Full Text] [Related]
15. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.
Balganesh M; Dinesh N; Sharma S; Kuruppath S; Nair AV; Sharma U
Antimicrob Agents Chemother; 2012 May; 56(5):2643-51. PubMed ID: 22314527
[TBL] [Abstract][Full Text] [Related]
16. Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.
Sun Z; Xu Y; Sun Y; Liu Y; Zhang X; Huang H; Li C
Microb Drug Resist; 2014 Dec; 20(6):525-32. PubMed ID: 24940805
[TBL] [Abstract][Full Text] [Related]
17. Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis.
Srivastava G; Tripathi S; Kumar A; Sharma A
Tuberculosis (Edinb); 2017 Jul; 105():18-27. PubMed ID: 28610784
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
19. 2,2,2-trifluoro-1-(1,4,5,6-tetrahydropyridin-3-yl)ethanone derivative as efflux pump inhibitor in Mycobacterium tuberculosis.
Halicki PCB; Vianna JS; Zanatta N; de Andrade VP; de Oliveira M; Mateus M; da Silva MV; Rodrigues V; Ramos DF; Almeida da Silva PE
Bioorg Med Chem Lett; 2021 Jun; 42():128088. PubMed ID: 33964440
[TBL] [Abstract][Full Text] [Related]
20. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
